Net Loss per Common Share available to Common Shareholders	6 Months Ended
Jun. 30, 2026
Net loss per common share available to common shareholders
Net Loss per Common Share available to Common Shareholders	Note 4. Net Loss per Common Share available to Common Shareholders Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. As more fully described in Note 8 of these consolidated financial statements, the Company declared a 15% stock dividend that was distributed on August 21, 2025 to stockholders of record as of August 7, 2025. In accordance with ASC 260, basic and diluted earnings per share amounts and weighted-average shares outstanding have been restated for all periods in 2025 presented to reflect the effect of this stock dividend. The Company did not pay any dividends during the first six months of 2026. As more fully described in Note 8 of these consolidated financial statements, on December 31, 2025, the Company completed the sale of a security offering that included prefunded warrants to purchase up to 1,609,114 shares of the Company’s common stock for $0.01 per share of which 973,000 remained outstanding as of June 30, 2026. In accordance with ASC 260-10-45-13, these pre-funded warrants, sometimes referred to as penny stock warrants due to their low exercise price ($0.0001/share), are considered outstanding shares for purpose of calculating earnings per share for the three-months and six-months-ended June 30, 2026. For the three-months and six-months ended June 30, 2026 and 2025, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 3,163,007 and 1,198,176, respectively. For the three months and six months ended June 30, 2026 and 2025, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive.

Net Loss per Common Share available to Common Shareholders

6 Months Ended

Jun. 30, 2026

Net loss per common share available to common shareholders

Net Loss per Common Share available to Common Shareholders

Note 4. Net Loss per Common Share available to Common Shareholders

Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive.

As more fully described in Note 8 of these consolidated financial statements, the Company declared a 15% stock dividend that was distributed on August 21, 2025 to stockholders of record as of August 7, 2025. In accordance with ASC 260, basic and diluted earnings per share amounts and weighted-average shares outstanding have been restated for all periods in 2025 presented to reflect the effect of this stock dividend. The Company did not pay any dividends during the first six months of 2026.

As more fully described in Note 8 of these consolidated financial statements, on December 31, 2025, the Company completed the sale of a security offering that included prefunded warrants to purchase up to 1,609,114 shares of the Company’s common stock for $0.01 per share of which 973,000 remained outstanding as of June 30, 2026. In accordance with ASC 260-10-45-13, these pre-funded warrants, sometimes referred to as penny stock warrants due to their low exercise price ($0.0001/share), are considered outstanding shares for purpose of calculating earnings per share for the three-months and six-months-ended June 30, 2026.

For the three-months and six-months ended June 30, 2026 and 2025, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 3,163,007 and 1,198,176, respectively. For the three months and six months ended June 30, 2026 and 2025, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive.